Product Description: Osimertinib-d6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
Applications: Cancer-Kinase/protease
Formula: C28H27D6N7O2
References: [1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61./[2][2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750.
CAS Number: 1638281-44-3
Molecular Weight: 505.64
Compound Purity: 99.97
Research Area: Cancer
Solubility: DMSO : 125mg/mL (ultrasonic;warming;heat to 60°C)
Target: EGFR
English
Deutsch
